Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path GlobeNewswire - Fri Dec 12, 6:00AM CST

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in...

BYSI : 1.8375 (-4.30%)
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 GlobeNewswire - Thu Dec 11, 6:00AM CST

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin...

BYSI : 1.8375 (-4.30%)
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 12, 6:00AM CST

Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with...

BYSI : 1.8375 (-4.30%)
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment GlobeNewswire - Wed Aug 13, 7:00AM CDT

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med  (Cell Press) Publication with MD Anderson Collaboration...

BYSI : 1.8375 (-4.30%)
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure GlobeNewswire - Mon Jul 7, 6:00AM CDT

BYSI : 1.8375 (-4.30%)
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors BayStreet.ca - Thu Jun 12, 9:16AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The future of cancer research appears to be drifting away from the public sector to the private sector,...

ONCY : 0.9547 (-1.58%)
BYSI : 1.8375 (-4.30%)
ELEV : 0.3650 (-2.12%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.5000 (-1.32%)
CRDF : 3.21 (+0.94%)
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting GlobeNewswire - Tue Jun 3, 6:00AM CDT

BYSI : 1.8375 (-4.30%)
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting GlobeNewswire - Wed May 28, 6:00AM CDT

BYSI : 1.8375 (-4.30%)
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Mon May 12, 3:30PM CDT

BYSI : 1.8375 (-4.30%)
BeyondSpring Files 2024 Annual Report on Form 10-K GlobeNewswire - Thu Mar 27, 6:05AM CDT

BYSI : 1.8375 (-4.30%)

Barchart Exclusives

This International Pharma Stock Just Hit 5-Year Highs Barchart - Fri Dec 26, 9:45AM CST
Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA offers international diversification and is favored by both Wall Street and individual investors. Today’s Featured Stock Valued... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot